Company intelligence / Profile preview

Neoware

Ownership: Private
Employees: ~15
Development stage: Other

Overview

NeoWare is a French biotechnology company specializing in the discovery of non-canonical neoantigens for personalized cancer immunotherapy. The company utilizes a proprietary platform to identify unique tumor-specific antigens that are often overlooked by traditional discovery methods, focusing on "dark matter" regions of the genome. By targeting these novel neoantigens, NeoWare aims to develop highly specific cancer vaccines and TCR-based therapies. The company is headquartered in Villejuif, France, and operates within the Gustave Roussy oncology ecosystem.

Therapeutic areas: Oncology
Modalities: VaccinePeptides
Industry: Biotech

Partnerships

Gustave RoussyINSERM

Beyond the preview

Go deeper on Neoware.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neoware.

Explore the full profile